State Pharmaceuticals Corporation O Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: State Pharmaceuticals Corporation O Pharmaceutical Import Records from India — 4 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

State Pharmaceuticals Corporation O — Pharmaceutical Importer Profile (2026) | 4 Products, $1.1M Trade | TransData Nexus

State Pharmaceuticals Corporation O

Pharmaceutical Importer · Sri Lanka · Advanced Diabetes Medications Focus · $1.1M Total Trade · DGFT Verified

State Pharmaceuticals Corporation O is a pharmaceutical importer based in Sri Lanka with a total trade value of $1.1M across 4 products in 4 therapeutic categories. Based on 23 verified import shipments from Indian Customs (DGFT) records, State Pharmaceuticals Corporation O is the #1 buyer in 1 product including Diagnostic. State Pharmaceuticals Corporation O sources from 53 verified Indian suppliers, with Wallace Pharmaceuticals Private Limited accounting for 7.4% of imports.

State Pharmaceuticals Corporation O — Import Portfolio & Supplier Network

State Pharmaceuticals Corporation O import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to State Pharmaceuticals Corporation O?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Wallace Pharmaceuticals Private Limited	$540.6K	12	7.4%
Reliance Life Sciences Private Limited	$525.3K	14	7.2%
Wockhardt Limited

What Formulations Does State Pharmaceuticals Corporation O Import?

Formulation	Value	Ships
Diagnostic kits meriscreen dengue ns1	$350.0K	7
Pharmaceutical products glytad	$250.0K	5
Nicardia retard 20MG 5x10t srl exp -	$243.0K	5
Elastic adhesive bandage b.p. 1993	$209.2K	6
63619 packs of gliclazide modified	$200.0K	4
Pantoprazole sodium delayed release tablets USP 40MG	$182.7K	7
Renown plus advance strength natural	$150.0K	3
Pharmaceutical article / ods / product / item glytad glyceryltrinitrate tablets BP 0.5 MG	$150.0K	3
Wosulin 30/70 100iu10ml vial -green card no pune-6 dated 28.03.2024 valid upto 31.03.2029 (lc no.	$135.3K	3
Wosulin 30/70 100iu10ml vial -green	$100.0K	2
Equirab 1000 IU/ 5ML [rabies	$100.0K	2
Pharmaceutical items- capsules-	$100.0K	2
Metronidazole tablets 200MG	$100.0K	2
Wosulin 30 70 100iu10ml vial green cardno 20956 dated 28 03 2019 valid upto 31 03	$100.0K	2
Fexofenadine hydrochloride tablets USP 120MG fegra 120 10x6 tablets qty	$100.0K	2

State Pharmaceuticals Corporation O imports 199 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gliclazide	Advanced Diabetes Medications	$450.0K	9	0.1%	14
2	Diagnostic	Medical Devices & Diagnostics	$350.0K	7	1.9%	1
3	Immunoglobulin	Other	$200.0K	4	0.1%	3
4	Rituximab	Advanced Oncology	$150.0K	3	0.8%	4

State Pharmaceuticals Corporation O imports 4 pharmaceutical products across 4 categories into Sri Lanka totaling $1.1M. The company is the #1 buyer for 1 product: Diagnostic.

State Pharmaceuticals Corporation O — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

State Pharmaceuticals Corporation O is a state-owned enterprise headquartered in Colombo, Sri Lanka. Established in 1971 under the State Industrial Corporations Act, it serves as the largest supplier of pharmaceuticals, surgical consumables, and laboratory chemicals in the country. The corporation's mission is to provide quality-assured healthcare items that are safe, effective, and affordable, while promoting the rational use of drugs among the public.

As a government procurement entity, State Pharmaceuticals Corporation O plays a pivotal role in Sri Lanka's pharmaceutical distribution network. It is the sole supplier of pharmaceuticals and related products to all institutions administered by the Ministry of Health. Additionally, it maintains a significant presence in the private sector, holding a 30% market share. The corporation operates a network of retail outlets known as Rajya Osu Salas (state drug shops), with 18 locations, and 36 franchise outlets, 48 distributors, and 20 authorized retailers across the country.

2Distribution Network

State Pharmaceuticals Corporation O's distribution network is extensive, encompassing both public and private healthcare sectors. Its retail outlets, Rajya Osu Salas, are strategically located to ensure nationwide coverage, with the original outlet in Colombo operating 24/7. The corporation's logistics capabilities are robust, enabling efficient supply chain management to meet the demands of various healthcare institutions and the general public. This extensive network underscores its critical role in ensuring the availability of essential medicines and healthcare products throughout Sri Lanka.

3Industry Role

In Sri Lanka's pharmaceutical supply chain, State Pharmaceuticals Corporation O functions primarily as a wholesaler and government procurement entity. It is the sole supplier of pharmaceuticals and related products to all institutions administered by the Ministry of Health, ensuring a centralized and standardized supply of essential medicines. In the private sector, it holds a 30% market share, supplying a wide range of pharmaceutical products to various private healthcare providers. This dual role enables the corporation to maintain a comprehensive presence across the healthcare spectrum, from public hospitals to private clinics and pharmacies.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — State Pharmaceuticals Corporation O

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

State Pharmaceuticals Corporation O's sourcing strategy reveals a high degree of concentration, with its top five imported products accounting for 100% of its imports from India. This indicates a strategic focus on a select range of products, potentially to leverage bulk purchasing advantages and ensure consistent quality. However, such concentration also poses risks, including supply chain disruptions if any of these key products face shortages or regulatory issues. The corporation's reliance on a limited number of suppliers for these products suggests a need for robust contingency planning and supplier relationship management to mitigate potential risks.

2Supply Chain Resilience

The resilience of State Pharmaceuticals Corporation O's supply chain is closely tied to its sourcing strategy. The corporation's focus on a limited number of key products and suppliers may enhance efficiency but also increases vulnerability to supply chain disruptions. The absence of backup suppliers for these critical products suggests a potential area of concern. To bolster resilience, the corporation could consider diversifying its supplier base and establishing contingency plans to address potential disruptions. Additionally, ensuring that all suppliers adhere to stringent regulatory standards and maintaining a diverse portfolio of formulations can further strengthen the supply chain's robustness.

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing the pharmaceutical sector in Sri Lanka. Established in 2015 through an Act of Parliament, the NMRA is responsible for ensuring the safety, efficacy, and quality of medicines, medical devices, and related products in the country. It regulates the manufacturing, importation, distribution, and sale of these products, as well as clinical trials conducted within Sri Lanka. The NMRA operates under the Ministry of Health and is governed by a board that provides strategic leadership and oversight. (nmra.gov.lk)

2Import Licensing & GMP

Import licensing is a critical component of Sri Lanka's pharmaceutical regulatory framework. The NMRA requires all pharmaceutical imports to be accompanied by valid import licenses, ensuring that only approved products enter the market. Additionally, the NMRA recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition facilitates the importation of high-quality pharmaceutical products that meet international standards. Wholesale distribution authorization is also mandated, ensuring that entities involved in the distribution of pharmaceuticals adhere to regulatory requirements and maintain the integrity of the supply chain. (nmra.gov.lk)

State Pharmaceuticals Corporation O — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

State Pharmaceuticals Corporation O's product strategy focuses on a select range of therapeutic areas, including advanced diabetes medications, medical devices and diagnostics, and other categories. The corporation's top five imported products—Gliclazide, Diagnostic, Immunoglobulin, Rituximab, and a category labeled 'Other'—account for the entirety of its imports from India. This concentrated approach suggests a strategic emphasis on high-demand, critical healthcare products. The market demand for these products is driven by the prevalence of conditions such as diabetes and the need for advanced diagnostic and therapeutic solutions in the Sri Lankan healthcare system.

2Sourcing Profile

State Pharmaceuticals Corporation O's sourcing strategy is characterized by a focus on generic drugs, particularly in the therapeutic areas of advanced diabetes medications and medical devices and diagnostics. The corporation's imports from India are exclusively finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This approach aligns with Sri Lanka's emphasis on affordable healthcare solutions and the promotion of generic drug use. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred sourcing partner for State Pharmaceuticals Corporation O.

Seller's Guide — How to Become a Supplier to State Pharmaceuticals Corporation O

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Sri Lankan market by partnering with State Pharmaceuticals Corporation O. The corporation's concentrated sourcing pattern suggests potential gaps in its current supplier base, particularly for products that align with its strategic focus areas. Indian exporters can capitalize on this by offering high-quality, cost-effective pharmaceutical formulations that meet the corporation's stringent regulatory and quality standards. Establishing strong, reliable partnerships and ensuring compliance with Sri Lankan regulatory requirements will be crucial for success in this market.

2Requirements & Qualifications

Indian exporters seeking to supply State Pharmaceuticals Corporation O and the Sri Lankan market must adhere to several key requirements.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — State Pharmaceuticals Corporation O

What products does State Pharmaceuticals Corporation O import from India?

State Pharmaceuticals Corporation O imports 4 pharmaceutical products across 4 categories. Top imports: Gliclazide ($450.0K), Diagnostic ($350.0K), Immunoglobulin ($200.0K), Rituximab ($150.0K).

Who supplies pharmaceuticals to State Pharmaceuticals Corporation O from India?

State Pharmaceuticals Corporation O sources from 53 verified Indian suppliers. The primary supplier is Wallace Pharmaceuticals Private Limited (7.4% of imports, $540.6K).

What is State Pharmaceuticals Corporation O's total pharmaceutical import value?

State Pharmaceuticals Corporation O's total pharmaceutical import value from India is $1.1M, based on 23 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does State Pharmaceuticals Corporation O focus on?

State Pharmaceuticals Corporation O imports across 4 categories. The largest: Advanced Diabetes Medications (39.1%), Medical Devices & Diagnostics (30.4%), Other (17.4%).

Get Full State Pharmaceuticals Corporation O Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.